Suven Pharma

Hyderabad, India Founded: 1989 • Age: 37 yrs Listed Acquired By Advent International
Contract manufacturing and development of APIs and formulations are provided.
Request Access
Report Incorrect Data
Page last updated

About Suven Pharma

Suven Pharma is a publicly listed company based in Hyderabad (India) founded in 1989, and was acquired by Advent International in December 2022. Contract manufacturing and development of APIs and formulations are provided. It operates on a Professional Services model. The company has 2,290 employees. Suven Pharma has completed 3 acquisitions, including Casper Pharma, NJ Bio and Sapala Organics. Its chief executive, as recorded, is Venkateswarlu Jasti. Its Indian entity Cohance Lifesciences Limited reported revenue of ₹2,303 Cr. Suven Pharma offers products and services including Formulation Development and Analytical Services, Process Research, Custom Synthesis, and Clinical Supplies Manufacturing & Packaging. Its focus areas include Pharmaceuticals. Its competitors include Indoco Remedies, Concord Biotech and BDR Pharmaceuticals Internationals; 1 of its 3 listed competitors has raised funding.

Company details

Suven Pharma is involved in providing contract development and manufacturing services for global pharmaceutical companies. The company focuses on formulation development, analytical services, process research, custom synthesis, and clinical supplies manufacturing. Operations are centered around supporting healthcare customers from lab to commercialization, with an emphasis on new chemical entities and fine chemical intermediates. Facilities and expertise are utilized to ensure efficient, safe, and cost-effective production across various pharmaceutical segments.

Recognitions & Rankings of Suven Pharma

India's Most Valuable Companies 2023 edition · Source: Hurun India
Rank#274
Valuation
₹14,361 Cr
2022 #327 2021 #268
  • Headquarters Hyderabad, India
  • Employees 2,290
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website suvenpharm.com
  • Acquired by Advent International (Dec 2022)
  • Legal Name Cohance Lifesciences Ltd
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹18,214 Cr

    COHANCE · NSE

  • Share Price
    ₹481.35

    +1.11% today

  • Revenue
    ₹2,269 Cr

    FY 2025-26 · -13.0% YoY

  • EBITDA
    ₹398 Cr

    Margin 17.5%

  • Net Profit
    ₹185 Cr

    FY 2025-26 · -59.5% YoY

  • P/E (TTM)
    170.3x

    P/B 4.7x

  • ROE
    4.0%

    ROCE 5.0%

  • Debt / Equity
    0.12

    Interest cover 17.7x

  • Investors
    Advent International
  • Employee Count
    2,290
  • Investments & Acquisitions
    Casper Pharma

    & 2 more

  • Acquired by
    Advent International

    (Dec 2022)

Products & Services of Suven Pharma

Suven Pharma offers a comprehensive portfolio of products and services, including Formulation Development and Analytical Services, Process Research, Custom Synthesis, and Clinical Supplies Manufacturing & Packaging.

Formulation Development and Analytical Services
Pharmaceutical Services

Services for formulation and analytical development are provided.

Process Research
Pharmaceutical Services

Efficient and cost-effective drug production is ensured here.

Custom Synthesis
Pharmaceutical Services

Novel molecules are accessed for cost-effective drug production.

Clinical Supplies Manufacturing & Packaging
Pharmaceutical Services

Clinical trial supplies are delivered meeting regulatory requirements.

Investors in Suven Pharma

Suven Pharma has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Advent International.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Advent International
Private equity firm focused on multiple sectors
adventinternational.comSao Paulo, Brazil
Premium access

Investor details for Suven Pharma

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Cohance Lifesciences Limited (Suven Pharma)

Cohance Lifesciences Limited is the primary company behind Suven Pharma. The boards of the 3 registered companies of Suven Pharma currently have 16 directors; the longest-serving is Venkateswarlu Jasti, appointed in 2010. 21 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Venkateswarlu Jasti
DIN 00278028
Managing Director04 Jan 201016 yrs 9 moSuven Life Sciences Limited
Seyed Ehtesham Hasnain
DIN 02205199
Director30 Apr 201016 yrs 5 moSuven Life Sciences Limited
Sudharani Jasti
DIN 00277998
Whole-time director04 Jan 201313 yrs 9 moSuven Life Sciences Limited
Santanu Mukherjee
DIN 07716452
Director15 May 20188 yrs 5 moSuven Life Sciences Limited
Ananthasai Padmaja Jasthi
DIN 07484630
Director14 Nov 20187 yrs 11 moSuven Life Sciences Limited
Jerry Jeyasingh
DIN 08589727
Director06 Nov 20196 yrs 11 moSuven Pharmaceuticals Limited
Kumarapuram Gopalakrishnan Ananthakrishnan
DIN 00019325
Director29 Sep 20233 yrs 1 moCohance Lifesciences Limited
Matangi Gowrishankar
DIN 01518137
Director29 Sep 20233 yrs 1 moCohance Lifesciences Limited
Vinod Rao
DIN 01788921
Director29 Sep 20233 yrs 1 moCohance Lifesciences Limited
Pankaj Patwari
DIN 08206620
Director29 Sep 20233 yrs 1 moCohance Lifesciences Limited
Shweta Jalan
DIN 00291675
Director09 Nov 20232 yrs 11 moCohance Lifesciences Limited
Pravin Udhyavara Bhadya Rao
DIN 06782450
Director09 Nov 20232 yrs 11 moCohance Lifesciences Limited
Vajja Sambasiva Rao
DIN 09233939
Director30 Jan 20242 yrs 8 moSuven Life Sciences Limited
Vinod Padikkal
DIN 07765484
Director12 Nov 20241 yr 11 moCohance Lifesciences Limited
Jai Shankar Krishnan
DIN 01519264
Director12 Nov 20241 yr 11 moCohance Lifesciences Limited
Umang Vohra
DIN 02296740
Whole-Time Director01 May 20265 moCohance Lifesciences Limited

People of Suven Pharma

5 people are tracked at Suven Pharma (5 in leadership); the tracked headcount is 2,290.

NameRoleGroup
Venkateswarlu Jasti
CEOLeadership
Srinivasu Metlapalli
Vice President EHS & ESGLeadership
Dr. Prasada Raju. V
Managing DirectorLeadership
Gaurav Bahadur
Chief Human Resources OfficerLeadership
Himanshu Agarwal
Chief Financial OfficerLeadership
Premium access

Complete people profiles for Suven Pharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Suven Pharma

Suven Pharma is a publicly listed company on the NSE with ticker symbol COHANCE in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date09 Mar 2020
  • Listed onNSE: SUVENPHAR · BSE: 543064
  • Listed entityCohance Lifesciences Ltd
  • Exchange sectorHealth technology
  • ISININE03QK01018
  • Share price₹445.60 (+1.89% on the day) · 2026-10-14
  • Market capitalisation₹16,727 Cr
  • Price to earnings161.5
  • EPS (diluted, trailing year)₹2.76
  • Volume (last session)465,259

Financials of Suven Pharma

Exchange-reported figures of Cohance Lifesciences Limited, the listed company behind Suven Pharma (NSE: COHANCE).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,269 Cr
-13.0% YoY
EBITDA
₹398 Cr
-49.1% YoY
Profit After Tax
₹185 Cr
-59.4% YoY
Net Worth
₹3,911 Cr
+7.2% YoY
Total Assets
₹5,130 Cr
+6.0% YoY
Total Debt
₹400 Cr
-17.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,2692,6081,0511,3401,3201,010834
Revenue growth-13.0%+148.1%-21.6%+1.5%+30.8%+21.1%-
EBITDA398781406574582443385
EBITDA margin+17.5%+30.0%+38.6%+42.8%+44.1%+43.9%+46.1%
Profit before tax207643406560668468404
Net profit185456267400403360312
Net profit margin+8.1%+17.5%+25.4%+29.8%+30.6%+35.6%+37.4%
EPS (₹)4.6819.1411.8016.1617.8314.2324.91
Balance sheet
Total assets5,1304,8382,1261,8141,6331,3301,039
Net worth3,9113,6492,0511,7351,5271,181845
Total debt40048665.0070.3497.12143186
Cash & bank59.6610250.5068.0147.319.6514.08
Net working capital1,0281,026426498505271255
Cash flow
Cash from operations368673358457330383407
Cash from investing(251)(388)(362)(195)(136)(311)(413)
Cash from financing(165)(327)(13.80)(242)(156)(75.66)7.32
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue422619545556549840676604
Revenue growth (YoY)-23.1%-26.3%-19.5%-8.0%+12.6%---
Other income12.25(1.84)6.1615.6014.1712.0521.5616.19
EBITDA1.1682.1790.49121104213237205
EBITDA margin+0.3%+13.3%+16.6%+21.8%+18.9%+25.4%+35.1%+34.0%
Depreciation49.5451.2346.9444.0245.1454.1743.5637.79
Interest6.749.199.118.7610.1810.4510.809.61
Profit before tax(42.87)19.9140.6083.7762.76161205174
Tax2.3211.6011.5817.3816.3643.7251.0935.92
Net profit(45.19)8.3129.0266.3946.40117153138
EPS (₹)(0.65)0.500.961.931.273.104.013.61
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,0302,5041,0511,3301,3201,010834
Revenue growth-18.9%+138.2%-21.0%+0.8%+30.8%+21.1%-
EBITDA425768406591582443385
EBITDA margin+20.9%+30.7%+38.6%+44.4%+44.1%+43.9%+46.2%
Profit before tax314650400579722414358
Net profit249503297422544306265
Net profit margin+12.3%+20.1%+28.2%+31.7%+41.2%+30.3%+31.8%
EPS (₹)5.9819.2911.6416.9921.9212.1221.22
Balance sheet
Total assets4,6264,5732,0931,8281,6271,215977
Net worth4,4804,2682,0281,7491,5211,065783
Total debt14630665.0170.3497.12143186
Cash & bank19.9936.4221.7346.2332.959.5613.96
Net working capital9591,005377473487271255
Cash flow
Cash from operations390686376493270330359
Cash from investing(204)(455)(362)(237)(90.36)(258)(367)
Cash from financing(203)(310)(39.99)(243)(156)(76.55)8.57
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue360568482498484769653594
Revenue growth (YoY)-25.6%-26.2%-26.3%-16.3%-0.9%---
Other income12.16(0.79)6.1226.3013.108.1921.4815.76
Total expenses333467384367387562421391
EBITDA26.4910097.9213196.10207233204
EBITDA margin+7.4%+17.6%+20.3%+26.3%+19.9%+26.9%+35.6%+34.2%
Depreciation34.3237.6633.3631.2031.3642.5838.0934.56
Interest2.125.175.255.246.807.0010.089.42
Profit before tax2.2156.4465.4312171.04166206175
Tax0.8021.8818.1426.4318.4742.8352.2036.20

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 29 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue422619545556549840676604
Revenue growth (YoY)-23.1%-26.3%-19.5%-8.0%+12.6%---
Other income12.25(1.84)6.1615.6014.1712.0521.5616.19
EBITDA1.1682.1790.49121104213237205
EBITDA margin+0.3%+13.3%+16.6%+21.8%+18.9%+25.4%+35.1%+34.0%
Depreciation49.5451.2346.9444.0245.1454.1743.5637.79
Interest6.749.199.118.7610.1810.4510.809.61
Profit before tax(42.87)19.9140.6083.7762.76161205174
Tax2.3211.6011.5817.3816.3643.7251.0935.92
Net profit(45.19)8.3129.0266.3946.40117153138
EPS (₹)(0.65)0.500.961.931.273.104.013.61
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,2692,6081,0511,3401,3201,010834
Revenue growth-13.0%+148.1%-21.6%+1.5%+30.8%+21.1%-
Other income34.0969.2161.9146.3613367.9766.33
Total expenses1,8711,827646766738567449
Employee cost50844813611810076.2365.10
EBITDA398781406574582443385
EBITDA margin+17.5%+30.0%+38.6%+42.8%+44.1%+43.9%+46.1%
Depreciation18716754.6047.9939.1031.6423.51
Interest37.2441.067.4512.818.5311.6723.07
Profit before tax207643406560668468404
Tax56.9215810514821410587.51
Net profit185456267400403360312
Net profit margin+8.1%+17.5%+25.4%+29.8%+30.6%+35.6%+37.4%
EPS (₹)4.6819.1411.8016.1617.8314.2324.91
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital38.2625.4625.4625.4625.4625.4612.73
Reserves & surplus3,8733,6042,0251,7101,5021,155832
Shareholders' funds (net worth)3,9113,6492,0511,7351,5271,181845
Minority interest1231440.000.000.000.000.00
Secured loans95.2425838.5869.1695.5799.7826.26
Unsecured loans30522826.421.181.5543.26160
Total debt40048665.0070.3497.12143186
Total liabilities5,1304,8382,1261,8141,6331,3301,039
Assets
Gross block4,2313,788924876694569457
Net block3,3693,107670663534441357
Capital work in progress17833417916529.9996.33102
Investments529337904536598542338
Inventories562467231313283201175
Sundry debtors681772134111236102117
Cash & bank balances59.6610250.5068.0147.319.6514.08
Loans & advances22722473.9310079.6271.0754.84
Total current assets1,5301,566489592647384361
Total current liabilities50154063.1393.69142113106
Net working capital1,0281,026426498505271255
Total assets5,1304,8382,1261,8141,6331,3301,039
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash96.6513864.8044.567.1811.7010.90
Net cash from operating activities368673358457330383407
Net cash from investing activities(251)(388)(362)(195)(136)(311)(413)
Net cash from financing activities(165)(327)(13.80)(242)(156)(75.66)7.32
Net change in cash(47.51)(41.67)(17.57)20.2437.38(4.51)0.79
Closing cash59.6610250.5068.0147.319.6514.08
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-13.0%+148.1%-21.6%+1.5%+30.8%+21.1%-
EBITDA growth-49.1%+92.5%-29.3%-1.3%+31.3%+15.1%-
PBT growth-67.8%+58.4%-27.5%-16.2%+42.8%+15.6%+156.3%
Net income growth-59.5%+70.5%-33.2%-0.9%+12.1%+15.3%-
Revenue CAGR (3Y)+19.2%+25.5%+1.4%+17.1%+51.8%--
EBITDA CAGR (3Y)-11.5%+10.3%-2.9%+14.3%+50.2%--
Profitability & leverage
Net income margin+6.6%+18.6%+28.6%+30.7%+34.4%+35.9%+38.0%
Return on capital employed+5.0%+20.1%+18.7%+33.2%+40.6%+40.5%+49.8%
Return on net worth+4.0%+17.0%+14.1%+25.2%+29.8%+35.8%+44.6%
Debt / equity0.120.100.040.050.090.160.19
Long-term debt / equity0.080.060.010.010.020.060.06
Interest cover17.726.682.122.431.572.846.39
Efficiency & per share
Fixed asset turnover0.571.111.171.712.091.972.07
Inventory turnover4.417.473.874.505.455.375.02
Debtors turnover3.125.768.607.727.799.206.30
EPS (₹)4.6819.1411.8016.1617.8314.2324.91
Dividend per share (₹)0.000.000.006.005.002.005.00
Book value per share (₹)102.23142.5780.5668.1659.9946.3866.37
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue360568482498484769653594
Revenue growth (YoY)-25.6%-26.2%-26.3%-16.3%-0.9%---
Other income12.16(0.79)6.1226.3013.108.1921.4815.76
Total expenses333467384367387562421391
EBITDA26.4910097.9213196.10207233204
EBITDA margin+7.4%+17.6%+20.3%+26.3%+19.9%+26.9%+35.6%+34.2%
Depreciation34.3237.6633.3631.2031.3642.5838.0934.56
Interest2.125.175.255.246.807.0010.089.42
Profit before tax2.2156.4465.4312171.04166206175
Tax0.8021.8818.1426.4318.4742.8352.2036.20
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,0302,5041,0511,3301,3201,010834
Revenue growth-18.9%+138.2%-21.0%+0.8%+30.8%+21.1%-
Other income44.7364.8456.6144.5518814.2418.12
Total expenses1,6061,736645739738567449
Employee cost38039713510910076.2365.10
EBITDA425768406591582443385
EBITDA margin+20.9%+30.7%+38.6%+44.4%+44.1%+43.9%+46.2%
Depreciation13414754.6043.1039.1031.6423.51
Interest22.4636.707.4512.758.5311.6621.81
Profit before tax314650400579722414358
Tax84.9215910414716410587.51
Net profit249503297422544306265
Net profit margin+12.3%+20.1%+28.2%+31.7%+41.2%+30.3%+31.8%
EPS (₹)5.9819.2911.6416.9921.9212.1221.22
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital38.2625.4625.4625.4625.4625.4612.73
Reserves & surplus4,4424,2232,0031,7241,4951,040770
Shareholders' funds (net worth)4,4804,2682,0281,7491,5211,065783
Secured loans95.2425038.5869.1695.5799.7826.26
Unsecured loans50.3955.2726.431.181.5543.26160
Total debt14630665.0170.3497.12143186
Total liabilities4,6264,5732,0931,8281,6271,215977
Assets
Gross block3,0692,739929713695569457
Net block2,2882,079670512534441357
Capital work in progress14633317916529.9996.32102
Investments1,1871,117893710600426276
Inventories540455231311283201175
Sundry debtors642730134110236102117
Cash & bank balances19.9936.4221.7346.2332.959.5613.96
Loans & advances20620063.7494.9175.0071.0754.83
Total current assets1,4071,422450562628384361
Total current liabilities44941773.3889.09141113106
Net working capital9591,005377473487271255
Total assets4,6264,5732,0931,8281,6271,215977
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash30.6111044.6530.217.0911.5810.90
Net cash from operating activities390686376493270330359
Net cash from investing activities(204)(455)(362)(237)(90.36)(258)(367)
Net cash from financing activities(203)(310)(39.99)(243)(156)(76.55)8.57
Net change in cash(17.50)(78.94)(26.19)12.8123.12(4.49)0.67
Closing cash19.9936.4221.7346.2332.959.5613.96
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-18.9%+138.2%-21.0%+0.8%+30.8%+21.1%-
EBITDA growth-44.7%+89.3%-31.3%+1.5%+31.4%+15.1%-
PBT growth-51.8%+62.3%-30.9%-19.8%+74.5%+15.8%+9997.0%
Net income growth-50.4%+69.6%-29.7%-22.4%+77.6%+15.4%-
Revenue CAGR (3Y)+15.1%+23.8%+1.4%+16.8%+51.8%--
EBITDA CAGR (3Y)-10.4%+9.7%-2.9%+15.4%+50.3%--
Profitability & leverage
Net income margin+11.3%+19.6%+28.2%+32.5%+42.3%+30.6%+32.4%
Return on capital employed+7.3%+20.6%+20.8%+34.3%+51.5%+38.8%+45.8%
Return on net worth+5.2%+15.6%+15.7%+26.5%+43.2%+33.4%+39.7%
Debt / equity0.050.060.040.050.090.180.20
Long-term debt / equity0.030.030.010.010.030.070.13
Interest cover7.715.902.122.331.572.836.04
Efficiency & per share
Fixed asset turnover0.701.371.281.892.091.972.07
Inventory turnover4.087.303.874.475.455.375.02
Debtors turnover2.965.808.647.697.799.206.30
EPS (₹)5.9819.2911.6416.9921.9212.1221.22
Dividend per share (₹)0.000.000.006.005.002.005.00
Book value per share (₹)117.10166.8879.6768.7259.7441.8461.50

Investments & Acquisitions by Suven Pharma

Suven Pharma has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Casper Pharma, NJ Bio and Sapala Organics.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
NJ Bio
Clinical development services are provided for biotechnology applications.
njbio.comNorth Brunswick, United States2018Dec 2024$64.4M
Sapala Organics
Research organization specializing in custom synthesis of various organic compounds
sapalaorganics.comHyderabad, India2005Jun 2024$27.47M
Casper Pharma
Specialty pharmaceuticals in key therapeutic areas are developed and commercialized.
casperpharma.comEast Brunswick, United States2016Apr 2022$20.5M
Premium access

Complete acquisition details for Suven Pharma

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Suven Pharma

6 dated milestones of Suven Pharma across 35 years, from founding to its latest funding, stage changes and deals.

  1. Founded Suven Pharma is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires Casper Pharma.
  4. Exit Acquired by Advent International.
  5. Acquisition Acquires Sapala Organics.
  6. Acquisition Acquires NJ Bio.

Competitors of Suven Pharma

Suven Pharma has 3 listed competitors in our database, 1 of them funded. They include Indoco Remedies, Concord Biotech and BDR Pharmaceuticals Internationals.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Indoco Remedies
indoco.com1947Mumbai, India6,291
APIs manufacturing and formulation services are provided in therapeutic segments.
Concord Biotech
concordbiotech.com2000Ahmedabad, India1,598
APIs and enzymes are manufactured through fermentation by the CDMO.
BDR Pharmaceuticals Internationals
bdrpharma.com2003Mumbai, India$88.16M1,864
APIs and finished products are developed and manufactured.
Premium access

Detailed competitors of Suven Pharma

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Suven Pharma

The website of Suven Pharma (suvenpharm.com) receives about 3.4K visits a month.

  • Monthly visits
    3.4K

    ▼ 22% vs previous month

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Suven Pharma (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M1,820
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M4,260
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Suven Pharma

Cohance Lifesciences: Names Mr. Abhimanyu Ojha As CFO Starting October 12, 2026, With Over 20 Years Of Finance Experience In Global Healthcare And Pharmaceuticals; Formerly Global CFO At Intas Pharmaceuticals.
Exchange Update • 20 days ago
Cohance Lifesciences: Jaggaiahpet API Facility Passes USFDA Inspection With Five Noted Observations.
Exchange Update • 1 month ago
Cohance's Umang Vohra says the worst is over; market looks for signs of recovery
Moneycontrol • 2 months ago
Reduce Cohance Lifesciences; target of Rs 365: ICICI Securities
Moneycontrol • 2 months ago
Cohance Life shares falls after USFDA flags five observations; reports losses in Q1
Moneycontrol • 2 months ago
COHANCE: Q1 revenue declined 23%, but growth and margin recovery are expected from H2, led by API Plus and Sapala
Quartr • 2 months ago
Cohance Lifesciences Says USFDA Conducted Inspection At Hyderabad Manufacturing Facility
Reuters • 2 months ago
COHANCE: Q1 FY27 revenue fell 23.1% YoY, but H2 growth is expected as recovery drivers strengthen
Quartr • 2 months ago
COHANCE: Q1 FY27 revenue fell 23.1% YoY, but H2 growth is expected as order flow and integration improve
Quartr • 2 months ago
Promoter pledges cross 90% threshold in more companies, may spur funding pressure in some pockets
Mint • 2 months ago
Premium access

Complete news archive for Suven Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Suven Pharma

Suven Pharma was founded in 1989.

Suven Pharma is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Venkateswarlu Jasti is the CEO of Suven Pharma, as recorded in our data.

Suven Pharma has 2,290 employees.

The primary company behind Suven Pharma, Cohance Lifesciences Limited, reported revenue of ₹2,303 Cr for FY 2026, down 13% year on year.

Suven Pharma is involved in providing contract development and manufacturing services for global pharmaceutical companies. The company focuses on formulation development, analytical services, process research, custom synthesis, and clinical supplies manufacturing. Operations are centered around supporting healthcare customers from lab to commercialization, with an emphasis on new chemical entities and fine chemical intermediates. Facilities and expertise are utilized to ensure efficient, safe, and cost-effective production across various pharmaceutical segments.

Suven Pharma's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Indoco Remedies.

Suven Pharma offers Formulation Development and Analytical Services, Process Research, Custom Synthesis, and Clinical Supplies Manufacturing & Packaging.

Yes, Suven Pharma is publicly traded on NSE under the ticker symbol COHANCE.

Suven Pharma has made 3 acquisitions, including Casper Pharma, NJ Bio, and Sapala Organics.

Suven Pharma has 1 investor. Key investors include Advent International.

Suven Pharma is associated with 3 legal entities: Cohance Lifesciences Limited, Suven Pharmaceuticals Limited, Suven Life Sciences Limited.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available